Thrombosis in COVID 2022: An Updated Narrative Review of Current Literature and Inpatient Management.
R I Med J (2013)
; 105(6): 36-40, 2022 08 01.
Article
in English
| MEDLINE | ID: covidwho-1958239
ABSTRACT
Early in the pandemic, it was recognized that infection with COVID-19 was associated with an increased incidence in both venous and arterial thrombotic events leading to poor patient outcomes. Given the rapid rise of the pandemic, anticoagulation strategies were initially based upon retrospective and observational data with few high-quality randomized control trials to help direct strategies regarding the use of thromboprophylaxis during hospitalization, empiric therapeutic anticoagulation, and extended-duration thromboprophylaxis after discharge. Over the past year, several randomized control trials have now been published evaluating these strategies. In this article, we hope to review the current literature surrounding the use of intermediate-dose thromboprophylaxis, empiric therapeutic anticoagulation, and the use of extended-duration thromboprophylaxis for patients hospitalized with COVID-19.
Keywords
Search on Google
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombosis
/
Venous Thromboembolism
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Language:
English
Journal:
R I Med J (2013)
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS